top of page
MVX-ONCO-1 Awarded the 2026 Pfizer Research Prize in Oncology (5 February 2026)
The award recognises a personalised cancer immunotherapy vaccine developed by UNIGE and HUG that originated at MaxiVax (now Release Therapeutics) Release Therapeutics (Release Tx) is pleased to announce that our research collaborators at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have been awarded the 2026 Pfizer Research Prize in Oncology for their work on the personalised cancer vaccine MVX-ONCO-1. [i] Established in 1992, the Pfizer Research Pr
Feb 53 min read
Release Therapeutics Announces New CEO to Advance Groundbreaking Treatment for Brain Disorders (30 January 2025)
Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study GENEVA, 30 January, 2025...
Jan 30, 20253 min read
Press Release: Release Therapeutics Announces New CEO to Drive Best-in-Class CNS Innovation
Release Tx Announces New CEO, aligning with the company’s recent pivot towards treating genetic disorders of the CNS without gene therapy
Jun 27, 20242 min read
Treating Genetic Disorders of the CNS without Gene Therapy (or what we’ve been up to here at Release Therapeutics)
Release Therapeutics' strategic pivot towards treating genetic disorders of the central nervous system without gene therapy.
Jun 15, 20246 min read
MaxiVAX transitions into Release Tx
We are pleased to announce that, with the recent progress in the development of its unique platform technology, MaxiVAX is morphing into...
Sep 15, 20231 min read
bottom of page